Abstract
We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose–response curves. We treated 16 patients with poor prognosis lymphoma in a phase I–II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72%. The inhibitory activity on colony forming unit granulocyte–macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose–response curves (21% measured vs 70% expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Broggini M, Italia C, Colombo T, Marmonti L and Donelli MG (1984) Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumours. Cancer Treat Rep 68: 739–747
Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymiopoulos C and Pannutti F (1992) Idarubicin metabolism and pharmacokinetic after intravenous and oral administration in cancer patients. A cross-over study. Cancer Chemother Pharmacol 30: 307–316
Campbell AD and Wicha MS (1988) Extracellular matrix and the haematopoietic microenvironment. J Lab Clin Med 112: 140–146
Case DC, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT and Gould J (1993) Phase II study of intravenous idarubicin in unfavourable non-Hodgkin's lymphoma. Leuk Lymphoma 10: 73–79
Chisesi T, Capnist G, De Dominicis E and Dini E (1988) A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 24: 681–684
Coutinho LH, Gilleece MH, De Winter EA, Will A and Testa NG (1993) Clonal and long-term cultures using human bone marrow. In: Haemopoiesis: a Practical Approach, Testa NG, Molineux G (eds), pp. 75–105. Oxford University Press: New York
Dodion P, Sanders C, Rombaut W, Mattelaer MA, Rozencweig M, Styckmans P and Kenis Y (1987) Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against normal myeloid stem cells and human malignant cells in vitro. Europ J Cancer Clin Oncol 23: 1909–1914
Dufour P, Mors R and Lamy T (1993) Idarubicin (IDA) and high-dose aracytine (HD-AraC): a new promising salvage treatment in relapsed or refractory non Hodgkin's lymphoma. Proc Am Soc Clin Oncol 12: 364 (abstract 1229)
Engert A (1995) Treatment of large cell lymphoma in second relapse. Lymphoma the next question. October 19–21, San Antonio. TX (abstract)
Garay G, Dupont J, Dragosky M, Nucifora E, Cacchione R, Schnidring P, Fernandez J, Abel-Alzueta A, Riveros D, Noviello V, Beguelin R, Campestri R, Albera C, Nicastro M and Triguboff E (1997) Combination salvage chemotherapy with MIZE (mesna-ifosfamide, idarubicin and etoposide) for relapsing or refractory lymphoma. Leuk Lymphoma 26: 595–602
Ghielmini M, Bosshard G, Capolongo L, Geroni MC, Pesenti E, Torri V, D'Incalci M, Cavalli F and Sessa C (1997) Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 75: 878–883
Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri W, D'Incalci M, Cavalli F and Sessa C (1998) Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolite. Cancer Chemoth Pharmacol 42: 235–240
Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P and Bonadonna G (1993) High-dose sequential chemotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease. A 6-year update. Ann Oncol 4: 889–891
Greenberg BR, Reynolds RD, Charron CB, Squillace KM, Lessins LS, Case DC and Gams RA (1993) Treatment of myelodysplastic syndrome with daily oral idarubicin. Cancer 71: 1989–1992
Gribaldo L, Bueren J and Deldar A (1996) The use of in vitro systems for evaluating haematotoxicity. Atla 24: 211–231
Kuffel M, Reid JM and James MM (1992) Anthracyclines and their C-13 alcohol metabolites. Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30: 51–57
Leglise MC, Darodes de Taily P, Vignot JL, Le Bot MA, Le Roux AM and Richè C (1996) A cellular model for drug interactions in hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis. Cell Biol Toxicol 12: 39–53
Liu LF, Rowe TC, Yang L, Tekey KM and Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365–15370
Minderman H, Linssen P, Van der Lely N, Wessels J, Boezeman J, De Witte F and Haanen C (1994) Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative status. Leukemia 8: 382–387
Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E and De Witte T (1993) Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 20: 47–52
Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D and Ghielmini M (1998) Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 9: 357–364
Robert J (1993) Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 24: 275–288
Salmon SE, Liu RM and Casazza AM (1981) Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6: 103–110
Schott B and Robert J (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol 38: 167–172
Twelves CJ (1995) Oral idarubicin in solid tumors chemotherapy. Clin Drug Invest 9: 39–54
Van Der Lely N, De Witte T, Raemaekers J, Schattenberg A and Haanen C (1989) Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery. Bone Marrow Transplant 4: 163–166
Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC and Banks PL (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 10: 1103–1111
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Corsini, C., Ghielmini, M., Mancuso, P. et al. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. Br J Cancer 82, 524–528 (2000). https://doi.org/10.1054/bjoc.1999.0957
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0957